SCHEMBL3393653

SCHEMBL3393653

CC(=O)OCc1ncc(C)cc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGBL2 Q5U5Z8 2/20 0.39
ELANE P08246 1/20 0.39
ALDH1A1 P00352 5/20 0.38
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37
HSD17B10 Q99714 3/20 0.35
KDM4E B2RXH2 2/20 0.35
ADORA2A P29274 1/20 0.35
LMNA P02545 1/20 0.34
CYP3A4 P08684 1/20 0.34
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
PDE10A Q9Y233 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28330994 0.85 NOS3 (0.40) AGBL2HSP90AA1HSP90AB1NOS3NOS1
SCHEMBL5734033 0.83 AGBL2 (0.37) AGBL2ELANEALDH1A1HSD17B10KDM4E
SCHEMBL20483536 0.82 SMN1; SMN2 (0.36) AGBL2ALDH1A1HSP90AA1HSP90AB1NOS3
SCHEMBL3393935 0.77 AGXT (0.40) AGBL2ELANEALDH1A1HSP90AA1HSP90AB1
SCHEMBL21241146 0.76 ALDH1A1 (0.42) AGBL2ELANEALDH1A1HSD17B10KDM4E
SCHEMBL2111929 0.75 ALDH1A1 (0.37) AGBL2ELANEALDH1A1HSP90AA1HSP90AB1
SCHEMBL3392712 0.73 CA2 (0.38) AGBL2ELANEALDH1A1HSP90AA1HSP90AB1
SCHEMBL3395441 0.73 AGXT (0.37) AGBL2ELANEALDH1A1HSP90AA1HSP90AB1
SCHEMBL8195868 0.73 HSP90AA1 (0.39) AGBL2ELANEALDH1A1HSP90AA1HSP90AB1
SCHEMBL31088058 0.72 ALDH1A1 (0.46) ELANEALDH1A1HSD17B10KDM4EADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2145888-A1 Deazapurine derivatives as HSP90-Inhibitors Conforma Therapeutics Corporation (US) 2010-01-20 EP disclosed
US-20070185064-A1 2-Aminopurine Analogs Having HSP90-Inhibiting Activity CONFORMA THERAPEUTICS CORPORATION (US) 2007-08-09 US disclosed
US-7138401-B2 2-aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION (US) 2006-11-21 US disclosed
EP-1670802-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS Conforma Therapeutic Corporation (US) 2006-06-21 EP disclosed
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION 2005-05-26 US disclosed
WO-2005028434-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS CONFORMA THERAPEUTICS CORPORATION (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity HSP90AB2P, HSP90AB1, HSP90AA1 AGBL2 551/4885ELANE 3895/4885ALDH1A1 827/4885
US-20070185064-A1 2-Aminopurine Analogs Having HSP90-Inhibiting Activity HSP90AB2P, HSP90AB1, HSP90AA1 AGBL2 551/4885ELANE 3895/4885ALDH1A1 827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.